Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Pilots Expansion Of Third-Party Review To Devices Without Guidance

This article was originally published in The Gray Sheet

Executive Summary

Only six of the twelve "accredited persons" have reviewed three or more 510(k) applications under the current third-party program, a requirement for participation in FDA's expanded third-party pilot.

You may also be interested in...



Third-Party Device Pilot Final Guidance Has Fewer Strings Attached

Accredited third-party reviewers will be allowed to evaluate 510(k)s in a medical specialty area for which they have not processed applications before under the Center for Devices and Radiological Health's Feb. 2 final guidance on third-party review.

Third-Party Device Pilot Final Guidance Has Fewer Strings Attached

Accredited third-party reviewers will be allowed to evaluate 510(k)s in a medical specialty area for which they have not processed applications before under the Center for Devices and Radiological Health's Feb. 2 final guidance on third-party review.

Oversight Chairman Greenwood Familiar With Third-Party Review Program

Any legislative proposal to expand FDA's third-party review program to applications containing clinical data would have a powerful ally in Rep. Jim Greenwood (R-Penn.), the newly named chair of the House Energy and Commerce/Oversight Subcommittee.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel